Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,639.50INR
22 Feb 2019
Change (% chg)

Rs53.20 (+2.06%)
Prev Close
Rs2,586.30
Open
Rs2,584.75
Day's High
Rs2,650.00
Day's Low
Rs2,555.70
Volume
1,378,159
Avg. Vol
986,553
52-wk High
Rs2,878.00
52-wk Low
Rs1,872.95

Latest Key Developments (Source: Significant Developments)

Dr.Reddy's Laboratories Says Co Was Issued Form 483 With 11 Observations After FDA Audit Of Hyderabad Plant
Friday, 8 Feb 2019 

Feb 8 (Reuters) - Dr.Reddy's Laboratories Ltd ::AUDIT OF CO'S FORMULATIONS MANUFACTURING PLANT - 3 AT BACHUPALLY, HYDERABAD BY U.S. FDA, HAS BEEN COMPLETED ON FEB. 8.CO HAS BEEN ISSUED FORM 483 WITH 11 OBSERVATIONS.  Full Article

Dr.Reddy's Laboratories Denies Wrongdoing After United Healthcare Services' Price-Fixing Complaint
Wednesday, 6 Feb 2019 

Feb 6 (Reuters) - Dr.Reddy's Laboratories Ltd ::CLARIFIES ON NEWS ITEM ON US INSURANCE FIRM NAMING CO IN PRICE-FIXING COMPLAINT.UNITED HEALTHCARE SERVICES FILED COMPLAINT AGAINST UNIT, 42 OTHERS INVOLVING A TOTAL OF 30 GENERIC DRUGS.COMPLAINT ALLEGES "OVERARCHING" PRICE FIXING CONSPIRACY TO RIG BIDS AND ALLOCATE CUSTOMERS WITH RESPECT TO 30 DRUGS.CO DENIES ANY WRONGDOING AND INTENDS TO VIGOROUSLY DEFEND AGAINST THESE CLAIMS.BELIEVES THAT THERE IS NO MATERIAL IMPACT OF COMPLAINT TO CO'S OPERATIONS OR CONSOLIDATED RESULTS.  Full Article

Indivior Enters Into Agreement With Alvogen
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Indivior Plc ::INDIVIOR ENTERS INTO AGREEMENT WITH ALVOGEN.ENTERED INTO AN AGREEMENT WITH ALVOGEN PINE BROOK LLC.TO CONTINUE TO PURSUE INFRINGEMENT CASES AGAINST ALVOGEN, APPEAL OF U.S. COURT'S NON-INFRINGEMENT DECISION RELATED TO U.S. PATENT 8,603,514.TO CONTINUE PURSUING INFRINGEMENT CASES INCLUDING DISTRICT COURT LITIGATION OF MORE RECENTLY LISTED ORANGE BOOK PATENTS FOR SUBOXONE FILM.DEAL ENJOINS ALVOGEN FROM SALE IN U.S. OF GENERIC BUPRENORPHINE, NALOXONE SUBLINGUAL FILM UNLESS COURT VACATES INJUNCTION AGAINST DR. REDDY'S.  Full Article

Dr. Reddy's Laboratories Continues Its Voluntary Nationwide Recall Of Levetiracetam
Monday, 4 Feb 2019 

Feb 4 (Reuters) - Dr.Reddy's Laboratories Ltd ::DR. REDDY'S LABORATORIES CONTINUES ITS VOLUNTARY NATIONWIDE RECALL OF LEVETIRACETAM IN 0.54% SODIUM CHLORIDE INJECTION 1500MG/100ML DUE TO MISLABELING.DR.REDDY'S LABORATORIES LTD - CONTINUING VOLUNTARY RECALL OF LOT ABD807 OF LEVETIRACETAM IN 0.54% SODIUM CHLORIDE INJECTION, 1,500 MG/100 ML.DR.REDDY'S LABORATORIES LTD - RECALL, WHICH BEGAN IN OCTOBER 2018, WAS ORIGINALLY INITIATED DUE TO A PRODUCT COMPLAINT RECEIVED FOR MISLABELING.DR.REDDY'S LABORATORIES LTD - LABEL ON EXTERNAL FOIL POUCH HAS PRODUCT INFORMATION AS LEVETIRACETAM IN 0.54% SODIUM CHLORIDE INJECTION.DR.REDDY'S LABORATORIES LTD - TO DATE, THERE HAVE BEEN NO REPORTS OF ADVERSE EVENTS RELATED TO LEVETIRACETAM RECALL.DR.REDDY'S LABORATORIES LTD - BATCH WAS DISTRIBUTED IN U.S.A. BETWEEN AUGUST 14, 2018 AND SEPTEMBER 5, 2018.  Full Article

India's Dr.Reddy's Laboratories Dec-Qtr Net PAT Up 65.3 Pct
Friday, 1 Feb 2019 

Feb 1 (Reuters) - Dr.Reddy's Laboratories Ltd ::DEC QUARTER CONSOL NET PROFIT AFTER TAX 5 BILLION RUPEES VERSUS PROFIT OF 3.03 BILLION RUPEES LAST YEAR.CONSENSUS FORECAST FOR DEC QUARTER CONSOL PROFIT WAS 3.94 BILLION RUPEES.DEC QUARTER CONSOL NET SALES 37.86 BILLION RUPEES VERSUS 36.16 BILLION RUPEES LAST YEAR.  Full Article

India's Dr.Reddy's Laboratories Launches Propofol Injectable Emulsion
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS LAUNCH OF PROPOFOL INJECTABLE EMULSION, USP APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION.  Full Article

Commonwealth Bank Of Australia Reports 8.95 Pct Passive Stake In Dr.Reddy's Laboratories As Of Dec. 31, 2018 - SEC Filing
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Dr.Reddy's Laboratories Ltd ::AS OF DEC. 31, 2018 - SEC FILING.  Full Article

Dr.Reddy's Labs Launches Sevelamer Carbonate For Oral Suspension In U.S.
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS LAUNCH OF SEVELAMER CARBONATE FOR ORAL SUSPENSION IN THE U.S. MARKET.  Full Article

Indivior Says Federal Court Declines Immediate Issue Of Mandate
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Indivior PLC ::FEDERAL COURT DECLINES IMMEDIATE ISSUE OF MANDATE.COURT OF APPEALS FOR FEDERAL CIRCUIT DECLINES TO IMMEDIATELY ISSUE MANDATE AFTER PRELIMINARY INJUNCTION RULING.U.S. COURT DENIED DR. REDDY'S MOTION TO IMMEDIATELY ISSUE MANDATE FOLLOWING CAFC'S RULING VACATING PRELIMINARY INJUNCTION.CAFC ALSO ORDERED THAT ANY PETITION FOR REHEARING BE SUBMITTED ON OR BEFORE DECEMBER 20, 2018.REDDY'S WILL REMAIN ENJOINED FROM RESUMING "AT-RISK" U.S. LAUNCH OF GENERIC BUPRENORPHINE-NALOXONE SUBLINGUAL FILM TILL AFTER MANDATE ISSUES.  Full Article

Dr.Reddy's Laboratories Launches Chlorthalidone Tablets, USP In U.S. Market
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - Dr.Reddy's Laboratories Ltd ::SAYS ANNOUNCES LAUNCH OF CHLORTHALIDONE TABLETS, USP IN U.S. MARKET.  Full Article

BUZZ-India's Dr.Reddy's gains most in nearly 13 weeks after U.S FDA report

** Shares of Indian drugmaker Dr.Reddy's Laboratories Ltd climbs as much as 4.9 pct to 2,689.65 rupees, in their biggest intraday pct gain since Nov. 11